An open-label single-centre pilot study to evaluate the safety and tolerability of PPS in subjects with MPS I
Source: Bratkovic, D. et al
November 23, 2021
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Paradigm Biopharmaceuticals. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Paradigm Biopharmaceuticals a question about this update.